If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Biden made several false or exaggerated claims about his early life: that he had earned three degrees in college, that he attended law school on a full scholarship, that he had graduated in the top half of his class, and that he had marched in the civil rights movement. The limited amount of other news about the presidential race amplified these disclosures, and on September 23, 1987, Biden withdrew his candidacy.
=== Sexuality and reproduction === Older adults are not necessarily sexually inactive nor have they lost interest in sex; although the frequency of sexual activity tends to decline with age. One survey in England of people aged 60–69 recorded 86% of men and 60% of women as sexually active. It is not possible to get pregnant from semen released in a commercial swimming pool without penetration. The sperm cells would be quickly killed by the chlorinated water and would not survive long enough to reach the vagina. An examination of the hymen is not an accurate or reliable indicator one has had penetrative sex; the tearing of the hymen may have been the result of some other event, and some are born without one. Virginity tests, such as the "two-finger" test, are unscientific. Hand size and foot size do not correlate with human penis size, but finger length ratio may. While pregnancies from sex between first cousins do carry a slightly elevated risk of birth defects, this risk is often exaggerated. The risk is 5–6% (similar to that of a woman in her early 40s giving birth), compared with a baseline risk of 3–4%. The effects of inbreeding depression, while still relatively small compared to other factors (and thus difficult to control for in a scientific experiment), become more noticeable if isolated and maintained for several generations. Having sex before a sporting event or contest is not physiologically detrimental to performance.
=== Nasal regurgitation === During swallowing, the soft palate and the uvula move superiorly to close off the nasopharynx, preventing food from entering the nasal cavity. When this process fails, the result is called nasal regurgitation. It is common in people with VPI, the myositides, and neuromuscular disease. Regurgitation of fluids in this way may also occur if a particularly high volume of liquid is regurgitated, or during vigorous coughing, for example being caused by the accidental inhalation of water. Due to the action of coughing preventing the uvula from blocking the nasopharynx, liquid may be expelled back through the nose.
=== Synopsis === Classical pharmacological studies on animals and isolated animal tissues showed that the principal actions of parenterally administered synephrine included raising blood-pressure, dilating the pupil, and constricting peripheral blood vessels. There is now ample evidence(what evidence?) that synephrine produces most of its biological effects by acting as an agonist (i.e. stimulating) at adrenergic receptors, with a distinct preference for the α1 over the α2 sub-type. However, the potency of synephrine at these receptors is relatively low (i.e. relatively large concentrations of the drug are required to activate them). The potency of synephrine at adrenergic receptors of the β-class (regardless of sub-type) is much lower than at α-receptors. There is some evidence that synephrine also has weak activity at 5-HT receptors, and that it interacts with TAAR1 (trace amine-associated receptor 1). In common with virtually all other simple phenylethanolamines (β-hydroxy-phenethylamines), the (R)-(−)-, or l-, enantiomer of synephrine is more potent than the (S)-(+)-, or d-, enantiomer in most, but not all preparations studied. However, the majority of studies have been conducted with a racemic mixture of the two enantiomers.
Proteinogenic amino acids Cysteine (Cys, C) Methionine (Met or M), an essential amino acid in humans Metabolic products: Cystine, a cysteine dimer, and an oxidation product of cysteine Homocysteine (Hcy) Homocystine, a homocysteine dimer, and an oxidation product of homocysteine Cystathionine, produced by the transsulfuration pathway S-Adenosyl methionine (SAM, SAMe, SAM-e, AdoMet), a common cofactor in methyltransferases S-Adenosyl homocysteine (SAH), a side product of biomethylation by methyltransferases
Sources: en.wikipedia.org
== History == Historically this equation arose as a variant on the Prony equation; this variant was developed by Henry Darcy of France, and further refined into the form used today by Julius Weisbach of Saxony in 1845. Initially, data on the variation of fD with velocity was lacking, so the Darcy–Weisbach equation was outperformed at first by the empirical Prony equation in many cases. In later years it was eschewed in many special-case situations in favor of a variety of empirical equations valid only for certain flow regimes, notably the Hazen–Williams equation or the Manning equation, most of which were significantly easier to use in calculations. However, since the advent of the calculator, ease of calculation is no longer a major issue, and so the Darcy–Weisbach equation's generality has made it the preferred one.
Although not without conflict, European Canadians' early interactions with First Nations and Inuit populations were relatively peaceful. First Nations and Métis peoples played a critical part in the development of European colonies in Canada, particularly for their role in assisting European coureurs des bois and voyageurs in their explorations of the continent during the North American fur trade. These early European interactions with First Nations would change from friendship and peace treaties to the dispossession of Indigenous lands through treaties. Settler colonialism reached a peak in the late 19th and early 20th centuries. The Canadian government funded Indian residential schools, administered by Christian churches, that are considered to be part of a genocide against Indigenous people due to the institutions' use of forced assimilation. In 2021, possible gravesites of Indigenous children were found near former Canadian residential schools, highlighting the cultural genocide against Indigenous peoples. A period of redress began with the formation of a reconciliation commission by the Government of Canada in 2008. This included acknowledgment of a cultural genocide, settlement agreements, and betterment of racial discrimination issues, such as addressing the plight of missing and murdered Indigenous women.
Experts in the United Kingdom have suggested that some psychoactive drugs that may be causing less harm to fewer users (although they are also used less frequently in the first place) are cannabis, psilocybin mushrooms, LSD, and MDMA; however, these drugs have risks and side effects of their own.
Graft copolymerization: The growing polystyrene chain reacts with a double bond of the polybutadiene. As a result, several polystyrene chains are attached to one polybutadiene. S represents in the figure the styrene repeat unit B the butadiene repeat unit. However, the middle block often does not consist of such depicted butane homo-polymer but of a styrene-butadiene co-polymer: SSSSSSSSSSSSSSSSSSSBBSBBSBSBBBBSBSSBBBSBSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS By using a statistical copolymer at this position, the polymer becomes less susceptible to cross-linking and flows better in the melt. For the production of SBS, the first styrene is homopolymerized via anionic copolymerization. Typically, an organometallic compound such as butyllithium is used as a catalyst. Butadiene is then added and after styrene again its polymerization. The catalyst remains active during the whole process (for which the used chemicals must be of high purity). The molecular weight distribution of the polymers is very low (polydispersity in the range of 1.05, the individual chains have thus very similar lengths). The length of the individual blocks can be adjusted by the ratio of catalyst to monomer. The size of the rubber sections, in turn, depends on the block length. The production of small structures (smaller than the wavelength of the light) ensure transparency. In contrast to PS-I, however, the block copolymer does not form any particles but has a lamellar structure.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.